Tesaro Inc. (TSRO), Breast International Group and the European Organization for Research and Treatment of Cancer announced a partnership for the Phase 3 clinical development of niraparib Monday morning.
Tesaro has been rising since the open of trade Monday and is now up 3.48 at $37.69. The stock has broken out of a 2-week range and has set a new high for the year.
For comments and feedback: editorial@rttnews.com